Thought Leader Liaison
ITF Therapeutics
Thought Leader Liaison
ITF Therapeutics
Develops and commercializes rare-disease therapies
Location: East Territory (Remote)
Reporting to: Director, Thought Leader Marketing and Engagement
About This Role:
ITF Therapeutics is seeking candidates for the role of Thought Leader Liaison covering the east region of the country. The Thought Leader Liaison (TLL) is a field-based marketing role responsible for developing and maintaining strategic relationships with key opinion leaders (KOLs), emerging experts, and influential healthcare professionals within DMD. The TLL serves as the commercial organization's primary point of contact for high-priority thought leaders and acts as the field-based extension of Marketing.
Working cross-functionally with Sales, Medical Affairs, Market Access, Patient Advocacy, and Marketing, the TLL drives strategic engagement, generates marketplace insights, supports speaker development, and facilitates compliant interactions that advance business objectives while maintaining adherence to all legal, regulatory, and compliance requirements.
What You’ll Do:
Who you Are and Required Skills:
Additional Information:
The base compensation range for this role is: $220,000 - $250,000. Compensation is determined through an analytical approach utilizing a combination of factors including, but not limited to, relevant skills & experience, job location, and internal equity.
Develops and commercializes rare-disease therapies
ITF Therapeutics is a division of Italfarmaco S.p.A. focused on developing and commercializing treatments for rare diseases in the U.S., especially Duchenne Muscular Dystrophy (DMD). The company works on early-stage research and clinical development, partnering with patient advocacy groups and clinical leaders to align programs with patient needs. Its lead program is DUVYZAT (givinostat), a histone deacetylase (HDAC) inhibitor aimed at DMD. Revenue comes from bringing these specialized therapies to market. Compared with competitors, ITF Therapeutics emphasizes collaboration with patient groups and clinicians, a pipeline-focused early-development approach, and a specialty in HDAC inhibitors for rare diseases. The company’s goal is to deliver effective treatments for rare-disease patients by advancing promising therapies through development and into commercialization.
Explore more opportunities at ITF Therapeutics